Treatment of kidney allograft with chronic antibody-mediated rejection using tocillizmab .

JRCT ID: jRCTs031180443

Registered date:28/03/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Chronic antibody-mediated rejection
• Date of first enrollment: 01/04/2018
• Target sample size: 20
• Study type: Interventional
• Intervention(s): The treatment of CAMR of kidney allograft with tocillizmab.

Outcome(s)

• Primary Outcome: The improvement of allograft function 1 year after the treatment
• Secondary Outcome: The long-term graft outcome after the treatment

Key inclusion & exclusion criteria

• Age minimum: 20 years old
• Age maximum: none
• Gender: Both

Include criteria

1. A patient with biopsy-proven chronic antibody-mediated rejection (CAMR) with positive donor-specific anti-HLA antibodies.
2. A patient which was resistant to the standard care of treatment for CAMR.
3. eGFR of patients > 30ml/min/1.73m2
4. A patient who willing to attend this study.

Exclude criteria

1. A patient with severe infection
2. A patient with active tuberculosis
3. A patient with malignancy
4. A patient having allergy to tocillizumab
5. A patient with severe complication which may affect the outcome of this study.
6. A patient with pregnancy

Related Information

• Primary Sponsor: SHISHIDO SEIICHIRO